Endocrine Abstracts

Introduction: Incretin based therapeutics have commonly been used in the last years for the management of patients with type 2 diabetes mellitus (DM). Linagliptin is a member of “dipeptidyl peptidase 4” (DPP-4) inhibitors and often preferred owing to some advantages over the others. We present a diabetic case developing skin findings after the initiation of linagliptin.Case: 66 year-old woman with a history of type 2 DM for 10 years was admitte...